Veru Q2 net loss narrows as expenses decline

Veru

Veru

VERU

0.00


Overview

  • US biopharma firm's fiscal Q2 net loss narrowed year-over-year

  • Research and development and administrative expenses both declined from prior year


Outlook

  • Company plans to prioritize internal cash for enobosarm development; advancement of sabizabulin depends on new funding


Result Drivers

  • EXPENSE REDUCTIONS - Lower research and development and administrative expenses narrowed net loss in Q2


Company press release: ID:nGNX6BHKLg


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

-$0.12

Q2 Net Income

-$2.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Veru Inc is $25.00, about 1,001.3% above its May 12 closing price of $2.27


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.